Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:CGON 11 January 2026 - 12 January 2026

CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology shares surged 29.3% to $54.20 after the company moved up its Phase 3 PIVOT-006 trial timeline, now expecting topline results in early 2026. Trading volume reached 7 million shares. Analysts raised price targets following the update and ahead of the JPMorgan Healthcare Conference. The trial enrolls over 360 bladder cancer patients and measures recurrence-free survival.
12 January 2026
··
CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next

CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next

CG Oncology shares surged 29% Friday to $54.20 after the company moved up its Phase 3 PIVOT-006 data release to early 2026. Morgan Stanley raised its price target to $93 and increased the program’s success probability to 70%. The company cited faster enrollment and no severe adverse events in recent data. CG Oncology will present at the J.P. Morgan Healthcare Conference on January 15.
11 January 2026
·
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology shares jumped nearly 29% Friday, closing at $54.20, after the company said topline Phase 3 trial data for its bladder cancer therapy will arrive in the first half of 2026, almost a year early. Morgan Stanley raised its price target to $93, citing the accelerated timeline. The PIVOT-006 trial enrolled over 360 patients at more than 90 sites.
11 January 2026
··

Stock Market Today

  • Nevada Temporarily Bans Prediction Market Firm Kalshi Over Gaming License Dispute
    March 20, 2026, 2:30 PM EDT. Kalshi, a prediction markets platform offering event-based contracts on sports, elections, and entertainment, was temporarily banned in Nevada by a 14-day restraining order from the First Judicial District Court. The ruling prohibits Kalshi from operating its derivatives exchange without a gaming license, marking the first state-level forced cessation for the company. The ban follows earlier Nevada cease-and-desist actions and precedes a likely extension through the legal case, said gaming attorney Daniel Wallach. The dispute comes amid mounting regulatory scrutiny nationally, including criminal charges from Arizona and ongoing battles in multiple states. Kalshi contends its sports contracts are financial swaps, not gambling, a view supported by the federal Commodity Futures Trading Commission, which claims jurisdiction over these markets. This case highlights tensions between state gambling laws and federally regulated prediction markets.
Go toTop